본문으로 건너뛰기
← 뒤로

Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.

Blood cancer discovery 2026 Vol.7(2) p. 306-330

Hartmann M, Schönung M, Rajak J, Maurer V, Hai L, Bauer K, Hakobyan M, Stäble S, Langstein J, Jardine L, Roelz R, Bohler S, Khabirova E, Maag AH, Vonficht D, Lebrecht D, Bernt KM, Tan K, Chen C, Alikarami F, Meyer J, Wang J, Boch T, Flore V, Lutsik P, Milsom MD, Raffel S, Buske C, Haas S, Haniffa M, Mallm JP, Behjati S, Bonder MJ, Fröhling S, Stieglitz E, Niemeyer CM, Hey J, Flotho C, Plass C, Erlacher M, Schlesner M, Lipka DB

📝 환자 설명용 한 줄

[UNLABELLED] Persistent fetal gene expression in childhood neoplasms is usually explained by a maturation block originating in the prenatal phase.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Hartmann M, Schönung M, et al. (2026). Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.. Blood cancer discovery, 7(2), 306-330. https://doi.org/10.1158/2643-3230.BCD-25-0246
MLA Hartmann M, et al.. "Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.." Blood cancer discovery, vol. 7, no. 2, 2026, pp. 306-330.
PMID 41348944

Abstract

[UNLABELLED] Persistent fetal gene expression in childhood neoplasms is usually explained by a maturation block originating in the prenatal phase. In contrast, reactivation of fetal genes in adult malignancies is considered a consequence of oncofetal reprogramming (OFR) and is associated with aggressive disease. By reconstructing epigenetic ontogeny in juvenile myelomonocytic leukemia (JMML), we identified a postnatal maturation state of JMML stem cells with high transcriptional plasticity indicative of OFR in high-risk disease. Similarly, postnatal activation of oncogenic signaling by inducible Ptpn11E76K mutation in mice triggered molecular plasticity and reactivation of fetal gene expression. Integrative multi-omics analysis revealed aberrant CD52 expression as a feature of high-risk JMML stem cells. Anti-CD52 treatment depleted JMML stem cells and blocked disease propagation in xenograft models. Our results challenge the prevailing maturation block model of pediatric leukemogenesis and establish RAS-associated stem cell plasticity as a determinant of OFR and potential therapeutic vulnerabilities in high-risk JMML.

[SIGNIFICANCE] Persistent fetal gene expression in pediatric malignancies is considered a consequence of prenatal maturation blockade. In this study, we demonstrate that oncogenic PTPN11 mutations enhance cellular plasticity. This leads to partial restoration of fetal molecular programs, creating new therapeutically exploitable vulnerabilities. See related commentary by Miao and Xu, pp. 168.

MeSH Terms

Leukemia, Myelomonocytic, Juvenile; Humans; Animals; Mice; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Cellular Reprogramming; Mutation; Epigenesis, Genetic